Drug
Alks 2680
Alks 2680: highest development phase Phase 2/3, developed by Alkermes. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 2680, 4mg NCT06767683 | Phase 2/3 | Narcolepsy Type 1 |
| ALKS 2680 NCT06843590 | Phase 2 | Idiopathic Hypersomnia |
| ALKS 2680 NCT06555783 | Phase 2 | Narcolepsy Type 2 |
| ALKS 2680 NCT06358950 | Phase 2 | Narcolepsy Type 1 |
Latest
No recent events.
Follow Alks 2680 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.